D. E. Shaw & Co., Inc. Verve Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$10.81 - $17.96 $952,987 - $1.58 Million	88,158 Added 39.7%	310,205 $4.12 Million
Q4 2023 Feb 14, 2024	BUY	$8.84 - $18.7 $1.96 Million - $4.15 Million	222,047 New	222,047 $3.1 Million
Q3 2022 Nov 14, 2022	SELL	$15.63 - $41.49 $1.36 Million - $3.61 Million	-87,063 Reduced 92.5%	7,062 $243,000
Q2 2022 Aug 15, 2022	BUY	$11.14 - $23.17 $34,745 - $72,267	3,119 Added 3.43%	94,125 $1.44 Million
Q1 2022 May 16, 2022	BUY	$20.92 - $39.36 $1.64 Million - $3.09 Million	78,380 Added 620.78%	91,006 $2.08 Million
Q4 2021 Feb 14, 2022	SELL	$31.94 - $54.82 $2.84 Million - $4.87 Million	-88,840 Reduced 87.56%	12,626 $466,000
Q3 2021 Nov 15, 2021	BUY	$46.0 - $73.99 $2.01 Million - $3.23 Million	43,647 Added 75.49%	101,466 $4.77 Million
Q2 2021 Aug 16, 2021	BUY	$31.92 - $60.25 $1.85 Million - $3.48 Million	57,819 New	57,819 $3.48 Million

174

74.8M

115K

144K

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $300M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.